187 related articles for article (PubMed ID: 12124174)
41. Extracellular Vesicles in Tumors: A Potential Mediator of Bone Metastasis.
Li S; Wang W
Front Cell Dev Biol; 2021; 9():639514. PubMed ID: 33869189
[TBL] [Abstract][Full Text] [Related]
42. The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis.
Napolitano F; Montuori N
J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33535668
[TBL] [Abstract][Full Text] [Related]
43. Regulation of Collective Metastasis by Nanolumenal Signaling.
Wrenn ED; Yamamoto A; Moore BM; Huang Y; McBirney M; Thomas AJ; Greenwood E; Rabena YF; Rahbar H; Partridge SC; Cheung KJ
Cell; 2020 Oct; 183(2):395-410.e19. PubMed ID: 33007268
[TBL] [Abstract][Full Text] [Related]
44. Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology.
Zhou W; Wu J; Zhang J; Liu X; Guo S; Jia S; Zhang X; Zhu Y; Wang M
Sci Rep; 2020 Jul; 10(1):12745. PubMed ID: 32728182
[TBL] [Abstract][Full Text] [Related]
45. The force awakens: metastatic dormant cancer cells.
Park SY; Nam JS
Exp Mol Med; 2020 Apr; 52(4):569-581. PubMed ID: 32300189
[TBL] [Abstract][Full Text] [Related]
46. Therapeutics targeting the fibrinolytic system.
Lin H; Xu L; Yu S; Hong W; Huang M; Xu P
Exp Mol Med; 2020 Mar; 52(3):367-379. PubMed ID: 32152451
[TBL] [Abstract][Full Text] [Related]
47. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
[TBL] [Abstract][Full Text] [Related]
48. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
[TBL] [Abstract][Full Text] [Related]
49. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
50. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
51. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.
Kubala MH; Punj V; Placencio-Hickok VR; Fang H; Fernandez GE; Sposto R; DeClerck YA
Cell Rep; 2018 Nov; 25(8):2177-2191.e7. PubMed ID: 30463014
[TBL] [Abstract][Full Text] [Related]
52. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.
Albrengues J; Shields MA; Ng D; Park CG; Ambrico A; Poindexter ME; Upadhyay P; Uyeminami DL; Pommier A; Küttner V; Bružas E; Maiorino L; Bautista C; Carmona EM; Gimotty PA; Fearon DT; Chang K; Lyons SK; Pinkerton KE; Trotman LC; Goldberg MS; Yeh JT; Egeblad M
Science; 2018 Sep; 361(6409):. PubMed ID: 30262472
[TBL] [Abstract][Full Text] [Related]
53. Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR.
Huang JM; Ren RY; Bao Y; Guo JC; Xiang W; Jing XZ; Shi J; Zhang GX; Li L; Tian Y; Kang H; Guo FJ
Front Pharmacol; 2018; 9():1016. PubMed ID: 30245631
[TBL] [Abstract][Full Text] [Related]
54. TEM8 functions as a receptor for uPA and mediates uPA-stimulated EGFR phosphorylation.
Zhang LC; Shao Y; Gao LH; Liu J; Xi YY; Xu Y; Wu C; Chen W; Chen HP; Wang YL; Duan HF; Hu XW
Cell Commun Signal; 2018 Sep; 16(1):62. PubMed ID: 30241478
[TBL] [Abstract][Full Text] [Related]
55. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Mahmood N; Mihalcioiu C; Rabbani SA
Front Oncol; 2018; 8():24. PubMed ID: 29484286
[TBL] [Abstract][Full Text] [Related]
56. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
[TBL] [Abstract][Full Text] [Related]
57. Tumor cell dormancy as an adaptive cell stress response mechanism.
Vera-Ramirez L; Hunter KW
F1000Res; 2017; 6():2134. PubMed ID: 29263786
[TBL] [Abstract][Full Text] [Related]
58. D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.
Eden G; Archinti M; Arnaudova R; Andreotti G; Motta A; Furlan F; Citro V; Cubellis MV; Degryse B
Cell Mol Life Sci; 2018 May; 75(10):1889-1907. PubMed ID: 29184982
[TBL] [Abstract][Full Text] [Related]
59. Synergistic inhibitory effects of an engineered antibody-like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model.
Zhou H; Wang H; Yu G; Wang Z; Zheng X; Duan H; Sun J
Oncol Lett; 2017 Nov; 14(5):5189-5196. PubMed ID: 29113154
[TBL] [Abstract][Full Text] [Related]
60. Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR.
Degryse B; Britto M; Shan CX; Wallace RG; Rochfort KD; Cummins PM; Meade G; Murphy RP
Data Brief; 2017 Dec; 15():600-605. PubMed ID: 29085875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
